Ovarian reserve in reproductive-aged patients with cancer before gonadotoxic treatment: a systematic review and meta-analysis
Meng Wu,Qingqing Zhu,Yibao Huang,Weicheng Tang,Jun Dai,Yican Guo,Jiaqiang Xiong,Jinjin Zhang,Su Zhou,Fangfang Fu,Mingfu Wu,Shixuan Wang
DOI: https://doi.org/10.1093/hropen/hoad024
2023-05-18
Human Reproduction Open
Abstract:Abstract STUDY QUESTION Does cancer itself, before any gonadotoxic treatment, affect ovarian function in reproductive-aged patients? SUMMARY ANSWER Our study revealed that women with cancer may have decreased ovarian reserve markers even before cancer therapy. WHAT IS KNOWN ALREADY With the field “oncofertility” improving rapidly, cancer therapy-mediated ovarian damage is well characterised. However, there is a controversy about whether cancer itself affects ovarian function before gonadotoxic treatment. STUDY DESIGN, SIZE, DURATION We conducted a systematic meta-analysis investigating the association between cancer and ovarian function prior to gonadotoxic treatment. Titles or abstracts related to ovarian reserve [e.g., anti-Müllerian hormone (AMH), antral follicle count (AFC) or basal follicle-stimulating hormone (FSH)] combined with titles or abstracts related to the exposure (e.g., cancer*, oncolog* or malignan*) were searched in PubMed, Embase and Web of Science databases from inception to Feb 1, 2022. PARTICIPANTS/MATERIALS, SETTING, METHODS We included cohort, case-control and cross-sectional studies in English that examined ovarian reserve in reproductive-aged patients (18-45 years) with cancer compared to age-matched controls before cancer treatment. The quality of the included studies was assessed by ROBINS-I. Fixed or random effects were conducted to estimate standard or weighted mean difference (SMD or WMD, respectively) and confidence interval (CI). Heterogeneity was assessed by the Q test and I2 statistics, and publication bias was evaluated by Egger’s and Begg’s tests. MAIN RESULTS AND THE ROLE OF CHANCE The review identified 17 eligible studies for inclusion. The results showed that cancer patients had lower serum AMH levels compared to healthy controls (SMD = -0.19, 95% CI: -0.34 to -0.03, P = 0.001), especially women with hematological malignancies (SMD = -0.62, 95% CI: -0.99 to -0.24, P = 0.001). The AFC was also decreased in patients with cancer (WMD = -0.93, 95%CI: -1.79 to -0.07, P = 0.033) compared to controls, while inhibin B and basal FSH levels showed no statistically significant differences. LIMITATIONS, REASONS FOR CAUTION Serum AMH and basal FSH levels in this meta-analysis showed high heterogeneity, and the small number of studies contributing to most subgroup analyses limited the heterogeneity analysis. Moreover, the studies for specific cancer subtypes may be too small to draw conclusions; more studies are needed to investigate the possible impact of cancer type and stage on ovarian function. WIDER IMPLICATIONS OF THE FINDINGS Our study confirmed the findings that cancer per se, especially hematological malignancies, negatively affects serum AMH level and AFC values of reproductive-aged women. However, the lower AMH levels and AFCs may also be due to the changes in ovarian physiology under oncological conditions, rather than actual lower ovarian reserves. Based on the meta-analysis, clinicians should raise awareness about the possible need for personalized approaches for young women with cancer who are interested in pursuing fertility preservation strategies before anticancer treatments. STUDY FUNDING/COMPETING INTEREST(S) This work was financially supported by the National Natural Science Foundation of China (no. 81873824, no. 82001514 and no.81902669) and the Applied Basic Research Program of Wuhan Municipal Bureau of Science and Technology (2019020701011436). The authors declare that they have no conflict of interest. REGISTRATION NUMBER PROSPERO (CRD42021235954) WHAT DOES THIS MEAN FOR PATIENTS? Over the past decades, the incidence of cancer in young women has increased constantly. Cancer therapy-mediated damage to the ovary is well characterized, but whether cancer itself, prior to cytotoxic treatment, affects ovarian function is controversial. Ovarian reserve is generally defined as the quantity of oocytes remaining in the ovary, and markers of ovarian reserve include the hormone levels of anti-Müllerian hormone (AMH), inhibin B and basal follicle-stimulating hormone (FSH) and the sonographically measured antral follicle count (AFC). Among these, AMH and AFC are the most favourable indicators of ovarian reserve. Based on the results of this meta-analysis, patients with cancer had significant decreased serum AMH levels and AFC values before cancer treatment, while basal FSH levels and inhibin B levels showed no difference between cancer patients and control groups. From these results, we suggest that cancer itself may have negative effects on ovarian reserve. These findings may provide valuable information to clinicians and patients for choosing effective fertility preservation measures before cancer treatment.